Yumab spinoff Corat to develop COVID-19 drug

By The Science Advisory Board staff writers

June 17, 2020 -- Yumab has announced that the first financing round of its spinoff Corat Therapeutics will be used to advance the development of COVID-19 antibody drug candidates.

Corat will continue the preclinical development of the lead antibody drug candidate for COVID-19, which was identified using Yumab's discovery of fully human monoclonal antibodies that neutralized activity against live SARS-CoV-2. Corat's efforts are led by managing director Thomas Schirrmann, PhD.

Clinical development may begin by the end of 2020, according to the company.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here